ARTICLE | Clinical News
Siamab Therapeutics preclinical data
October 10, 2016 7:00 AM UTC
In a mouse xenograft model of ovarian cancer, Siamab’s ST1 ADC composed of a sialosyl-Tn antigen (sTn) antibody and monomethyl auristatin E (MMAE) given every 7 days significantly reduced tumor volum...